Phocas Financial Corp. lifted its stake in shares of Diplomat Pharmacy Inc (NYSE:DPLO) by 142.9% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 663,187 shares of the company’s stock after purchasing an additional 390,168 shares during the quarter. Diplomat Pharmacy comprises about 1.1% of Phocas Financial Corp.’s investment portfolio, making the stock its 23rd largest position. Phocas Financial Corp.’s holdings in Diplomat Pharmacy were worth $13,310,000 as of its most recent filing with the Securities & Exchange Commission.
Several other large investors also recently bought and sold shares of DPLO. Cortina Asset Management LLC grew its stake in shares of Diplomat Pharmacy by 538.8% during the 3rd quarter. Cortina Asset Management LLC now owns 1,616,792 shares of the company’s stock worth $33,484,000 after purchasing an additional 1,363,696 shares during the period. Dimensional Fund Advisors LP grew its stake in shares of Diplomat Pharmacy by 149.7% during the 3rd quarter. Dimensional Fund Advisors LP now owns 894,669 shares of the company’s stock worth $18,528,000 after purchasing an additional 536,412 shares during the period. Point72 Asset Management L.P. acquired a new position in shares of Diplomat Pharmacy during the 3rd quarter worth $8,226,000. JPMorgan Chase & Co. grew its stake in shares of Diplomat Pharmacy by 99.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 564,120 shares of the company’s stock worth $11,571,000 after purchasing an additional 281,498 shares during the period. Finally, BlackRock Inc. grew its stake in shares of Diplomat Pharmacy by 3.6% during the 4th quarter. BlackRock Inc. now owns 6,754,710 shares of the company’s stock worth $135,566,000 after purchasing an additional 237,500 shares during the period. 64.64% of the stock is currently owned by institutional investors and hedge funds.
A number of equities analysts have recently weighed in on DPLO shares. Mizuho set a $25.00 price target on shares of Diplomat Pharmacy and gave the stock a “hold” rating in a research note on Wednesday, January 24th. Deutsche Bank cut shares of Diplomat Pharmacy from a “buy” rating to a “hold” rating and increased their price objective for the company from $22.00 to $29.00 in a research note on Friday, February 2nd. Leerink Swann set a $30.00 price objective on shares of Diplomat Pharmacy and gave the company a “buy” rating in a research note on Tuesday, February 27th. Lake Street Capital assumed coverage on shares of Diplomat Pharmacy in a research note on Friday, February 9th. They issued a “buy” rating and a $35.00 price objective on the stock. Finally, Needham & Company LLC increased their price objective on shares of Diplomat Pharmacy from $24.00 to $26.00 and gave the company a “buy” rating in a research note on Monday, January 8th. Eight analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Diplomat Pharmacy presently has an average rating of “Hold” and an average price target of $25.38.
Shares of Diplomat Pharmacy Inc (NYSE:DPLO) opened at $23.20 on Tuesday. The company has a market cap of $1,685.07, a PE ratio of 110.48 and a beta of 1.32. Diplomat Pharmacy Inc has a 12 month low of $14.00 and a 12 month high of $27.78. The company has a quick ratio of 0.66, a current ratio of 0.97 and a debt-to-equity ratio of 0.70.
Diplomat Pharmacy (NYSE:DPLO) last released its earnings results on Monday, February 26th. The company reported $0.18 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.16 by $0.02. The company had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.17 billion. Diplomat Pharmacy had a net margin of 0.35% and a return on equity of 8.89%. The firm’s quarterly revenue was up .9% on a year-over-year basis. During the same period in the prior year, the firm earned $0.08 EPS. equities analysts anticipate that Diplomat Pharmacy Inc will post 0.94 earnings per share for the current year.
In other Diplomat Pharmacy news, Director Philip R. Hagerman sold 2,150,000 shares of the company’s stock in a transaction dated Friday, March 9th. The shares were sold at an average price of $20.65, for a total value of $44,397,500.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 30.20% of the stock is currently owned by corporate insiders.
ILLEGAL ACTIVITY WARNING: “Diplomat Pharmacy Inc (DPLO) Stake Boosted by Phocas Financial Corp.” was posted by Stock Observer and is the sole property of of Stock Observer. If you are viewing this news story on another domain, it was copied illegally and reposted in violation of US and international copyright legislation. The original version of this news story can be viewed at https://www.thestockobserver.com/2018/03/20/diplomat-pharmacy-inc-dplo-stake-boosted-by-phocas-financial-corp.html.
About Diplomat Pharmacy
Diplomat Pharmacy, Inc (Diplomat) operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company operates through specialty pharmacy services segment. The Company’s primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialty infusion therapy, and various other serious and/or long-term conditions.
Want to see what other hedge funds are holding DPLO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Diplomat Pharmacy Inc (NYSE:DPLO).
Receive News & Ratings for Diplomat Pharmacy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy and related companies with MarketBeat.com's FREE daily email newsletter.